Targeted Therapeutics Market

Targeted Therapeutics Market (Type: Monoclonal Antibodies and Small Molecule; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Targeted Therapeutics Market Outlook 2031

  • The global industry was valued at US$ 69.8 Bn in 2022
  • It is expected to grow at a CAGR of 6.4% from 2023 to 2031 and reach US$ 118.6 Bn by the end of 2031

Analyst Viewpoint

Increase in prevalence of cancer is one of the prominent factors driving the targeted therapeutics industry. Targeted therapeutics result in alteration of proteins in cancer cells, thus causing their death.

They also prevent the formation of new cells, thereby cutting off blood supply to tumor, and deliver toxins that act as predators to cancer cells without causing any harm to healthy cells. Rise in awareness programs regarding the benefits of targeted therapeutics is also contributing to targeted therapeutics market growth.

Companies operating in the global targeted therapeutics industry are exploring the adoption of new approaches such as synthetic biology, which harnesses the immune system with greater precision.

Leading players are closely observing the latest targeted therapeutics market trends and embracing advanced and innovative technologies to develop precision medicines of the future.

Targeted Therapeutics Market Overview

Targeted therapeutics, a type of cancer treatment, refers to the usage of drugs for targeting specific proteins and genes that help in the proliferation of cancer cells. These therapeutics can be used either solitarily or in combination with chemotherapy.

Currently, targeted therapeutics are not available for all types of cancers. However, it remains a vast arena to be explored. Several targeted therapies are in the pipeline.

The ongoing trend is that of deploying precision medicines for cancer treatment. Targeted therapeutics use specific information about the patient’s tumor for helping in diagnosis, treatment, and prognosis.

In other words, personalized molecular therapies enable clinicians to work out individual vulnerability as a response to infection. These therapies can also gauge the inter-individual heterogeneity.

Biomarker-guided therapeutic approaches are gaining traction across the globe, as biomarkers help in facilitating adaptive clinical trial designs. These designs can be used to measure the effects of drug treatment in patients throughout trial, including toxicity responses and clinical efficacy.

Attribute Detail
Market Drivers
  • Growth in Prevalence of Cancer
  • Rise in Awareness Campaigns Regarding Cancer Therapeutics

Increase in Prevalence of Cancer Boosting Targeted Therapeutics Market Size

Air pollution and adoption of unhealthy habits are some of the factors that may cause cancer. For instance, smoking and excessive consumption of alcohol can result in cancers of the lung and lever. Chewing of tobacco is reported to cause oral cancer.

The WHO states that around 1.3 billion people consume tobacco products across the globe; of these, 80% people belong to middle- and low-income countries.

As per the WHO’s International Agency for Research on Cancer (IARC), the year 2022 witnessed 20 million novel cancer cases. It further states that 20% of the global population develops cancer in their lifetime.

Other findings state that lung cancer is the most prevalent, followed by breast cancer, colorectal cancer, prostate cancer, and stomach cancer. Certain countries in sub-Saharan Africa also witnessed the onslaught of cervical cancer in 2022.

This surge in prevalence of various types of cancers worldwide is driving the targeted therapeutics industry growth.

Rise in Awareness Campaigns Creating Lucrative Targeted Therapeutics Market Opportunities for Companies

As per the WHO, 34 million new cases of cancer are likely to be diagnosed by 2050, a 77% increase compared to that in 2022. This number can be brought under control through regular awareness campaigns regarding the prevalence of cancer.

In 2020, 194 countries aligned with the WHO’s global strategy aimed toward elimination of cervical cancer worldwide. Such initiatives are boosting the demand for targeted therapeutics worldwide.

In 2021, ‘Let’s demask cancer,’ a web platform, launched an exclusive website with information and a comic book. The website stresses upon the importance of early diagnosis of colon cancer and also highlights personalized therapeutics.

Research states that colorectal cancer takes five to 10 years to transform from benign to a malignant one. If detected early, customized therapies can be applied and the lives of patients can be saved.

Thus, growth in awareness campaigns regarding the importance of targeted therapeutics in cancer is augmenting the targeted therapeutics market.

Regional Outlook

Attribute Detail
Leading Region North America

As per the targeted therapeutics market analysis, demand for individualized gene therapy solutions was high in North America in 2022. This trend is anticipated to continue during the forecast period.

Large targeted therapeutics market share of North America can be ascribed to the high incidence of cancer in the region. As per the American Cancer Society, the number of new cancer cases in the U.S. stood at 1.95 million in 2023. According to Statistics Canada, there were 233,900 cases of cancer in 2022.

Europe and Asia Pacific also recorded substantial market progress in 2022. According to the OECD, the year 2022 witnessed 2.74 million new cases of cancer in the 27 EU member states. This number is expected to rise by 2% to 3% every year.

On the other hand, Southeast Asia reported 2.2 million new cases of cancer and 1.4 million cancer-related fatalities in 2020, as per the WHO. Thus, the targeted therapeutics market forecast appears positive in Europe and Asia Pacific.

Analysis of Key Players

Companies operating in the global targeted therapeutics landscape are focusing on launching new products and obtaining quick product approvals. Prompt response by the regulatory bodies regarding product approval is enabling companies to expand their product portfolio.

In May 2021, the U.S.FDA approved Janssen’s Rybrevant (amivantamab), a bispecific antibody directed against epidermal growth factor (EGF) and MET receptors, for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

Sanofi, GlaxoSmithKline plc, Takeda Pharmaceutical Company Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Seagen, Inc., Bayer AG, Amgen, Inc., and Bristol-Myers Squibb Company are some of the key players covered in the targeted therapeutics market report.

These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.

Targeted Therapeutics Market Snapshot

Attribute Detail
Market Size in 2022 US$ 69.8 Bn
Market Forecast (Value) in 2031 US$ 118.6 Bn
Growth Rate (CAGR) 6.4%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Type
    • Monoclonal Antibodies (Angiogenesis Inhibitors, HER-2 Targeted Agents, and Anti-CD20 Monoclonal Antibodies)
    • Small Molecule (Tyrosine Kinase Inhibitors)
  • Application
    • Breast Cancer
    • Colorectal Cancer
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Multiple Sclerosis
    • Renal Cancer
    • Wet Age-related Macular Degeneration
    • Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer)
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC
Companies Profiled
  • Sanofi
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca
  • Seagen, Inc.
  • Bayer AG
  • Amgen, Inc.
  • Bristol-Myers Squibb Company
Customization Scope Available Upon Request
Pricing Available Upon Request

Frequently Asked Questions

How big was the global targeted therapeutics market in 2022?

It was valued at US$ 69.8 Bn in 2022

How is targeted therapeutics business expected to grow during the forecast period?

It is projected to grow at a CAGR of 6.4% from 2023 to 2031

What are the key factors driving the demand for targeted therapeutics?

Growth in incidence of cancer and rise in awareness campaigns regarding cancer therapeutics

Which targeted therapeutics distribution channel segment held the largest share in 2022?

The hospital pharmacies segment accounted for the largest share in 2022

Which region dominated the global targeted therapeutics landscape in 2022?

North America was the dominant region in 2022

Who are the key targeted therapeutics manufacturers?

Sanofi, GlaxoSmithKline plc, Takeda Pharmaceutical Company Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Seagen, Inc., Bayer AG, Amgen, Inc., and Bristol-Myers Squibb Company

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Targeted Therapeutics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Type Definition

        4.1.2. Industry Evolution/Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Targeted Therapeutics Market Analysis and Forecast, 2017–2031

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Key Type/Brand Analysis

    5.3. Key Mergers & Acquisitions

    5.4. COVID-19 Pandemic Impact on Industry

6. Global Targeted Therapeutics Market Analysis and Forecast, by Type

    6.1. Introduction & Definition

    6.2. Key Findings/Developments

    6.3. Market Value Forecast, by Type, 2017–2031

        6.3.1. Monoclonal Antibodies

            6.3.1.1. Angiogenesis Inhibitors

            6.3.1.2. HER-2 Targeted Agents

            6.3.1.3. Anti-CD20 Monoclonal Antibodies

        6.3.2. Small Molecule

            6.3.2.1. Tyrosine Kinase Inhibitors

                6.3.2.1.1. mTOR Inhibitors

                6.3.2.1.2. PARP Inhibitors

    6.4. Market Attractiveness Analysis, by Type

7. Global Targeted Therapeutics Market Analysis and Forecast, by Application

    7.1. Introduction & Definition

    7.2. Key Findings/Developments

    7.3. Market Value Forecast, by Application, 2017–2031

        7.3.1. Breast Cancer

        7.3.2. Colorectal Cancer

        7.3.3. Leukemia

        7.3.4. Lung Cancer

        7.3.5. Lymphoma

        7.3.6. Multiple Sclerosis

        7.3.7. Renal Cancer

        7.3.8. Wet Age-related Macular Degeneration

        7.3.9. Others (Ovarian Cancer, Fallopian Tube cancer, Prostate Cancer, and Pancreatic Cancer)

    7.4. Market Attractiveness Analysis, by Application

8. Global Targeted Therapeutics Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings/Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017–2031

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Targeted Therapeutics Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region, 2017–2031

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Targeted Therapeutics Market Analysis and Forecast

    10.1. Introduction

    10.2. Key Findings

    10.3. Market Value Forecast, by Type, 2017–2031

        10.3.1. Monoclonal Antibodies

            10.3.1.1. Angiogenesis Inhibitors

            10.3.1.2. HER-2 Targeted Agents

            10.3.1.3. Anti-CD20 Monoclonal Antibodies

        10.3.2. Small Molecule

            10.3.2.1. Tyrosine Kinase Inhibitors

                10.3.2.1.1. mTOR Inhibitors

                10.3.2.1.2. PARP Inhibitors

    10.4. Market Value Forecast, by Application, 2017–2031

        10.4.1. Breast Cancer

        10.4.2. Colorectal Cancer

        10.4.3. Leukemia

        10.4.4. Lung Cancer

        10.4.5. Lymphoma

        10.4.6. Multiple Sclerosis

        10.4.7. Renal Cancer

        10.4.8. Wet Age-related Macular Degeneration

        10.4.9. Others (Ovarian Cancer, Fallopian Tube cancer, Prostate

    10.5. Market Value Forecast, by Distribution Channel, 2017–2031

        10.5.1. Hospital Pharmacies

        10.5.2. Retail Pharmacies

        10.5.3. Online Pharmacies

    10.6. Market Value Forecast, by Country, 2017–2031

        10.6.1. U.S.

        10.6.2. Canada

    10.7. Market Attractiveness Analysis

        10.7.1. By Type

        10.7.2. By Application

        10.7.3. By Distribution Channel

        10.7.4. By Country

11. Europe Targeted Therapeutics Market Analysis and Forecast

    11.1. Introduction

    11.2. Key Findings

    11.3. Market Value Forecast, by Type, 2017–2031

        11.3.1. Monoclonal Antibodies

            11.3.1.1. Angiogenesis Inhibitors

            11.3.1.2. HER-2 Targeted Agents

            11.3.1.3. Anti-CD20 Monoclonal Antibodies

        11.3.2. Small Molecule

            11.3.2.1. Tyrosine Kinase Inhibitors

                11.3.2.1.1. mTOR Inhibitors

        11.3.3. 11.3.2.1.2 PARP Inhibitors

    11.4. Market Value Forecast, by Application, 2017–2031

        11.4.1. Breast Cancer

        11.4.2. Colorectal Cancer

        11.4.3. Leukemia

        11.4.4. Lung Cancer

        11.4.5. Lymphoma

        11.4.6. Multiple Sclerosis

        11.4.7. Renal Cancer

        11.4.8. Wet Age-related Macular Degeneration

        11.4.9. Others (Ovarian Cancer, Fallopian Tube cancer, Prostate

    11.5. Market Value Forecast, by Distribution Channel, 2017–2031

        11.5.1. Hospital Pharmacies

        11.5.2. Retail Pharmacies

        11.5.3. Online Pharmacies

    11.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.6.1. Germany

        11.6.2. U.K.

        11.6.3. France

        11.6.4. Italy

        11.6.5. Spain

        11.6.6. Rest of Europe

    11.7. Market Attractiveness Analysis

        11.7.1. By Type

        11.7.2. By Application

        11.7.3. By Distribution Channel

        11.7.4. By Country/Sub-region

12. Asia Pacific Targeted Therapeutics Market Analysis and Forecast

    12.1. Introduction

    12.2. Key Findings

    12.3. Market Value Forecast, by Type, 2017–2031

        12.3.1. Monoclonal Antibodies

            12.3.1.1. Angiogenesis Inhibitors

            12.3.1.2. HER-2 Targeted Agents

            12.3.1.3. Anti-CD20 Monoclonal Antibodies

        12.3.2. Small Molecule

            12.3.2.1. Tyrosine Kinase Inhibitors

                12.3.2.1.1. mTOR Inhibitors

                12.3.2.1.2. PARP Inhibitors

    12.4. Market Value Forecast, by Application, 2017–2031

        12.4.1. Breast Cancer

        12.4.2. Colorectal Cancer

        12.4.3. Leukemia

        12.4.4. Lung Cancer

        12.4.5. Lymphoma

        12.4.6. Multiple Sclerosis

        12.4.7. Renal Cancer

        12.4.8. Wet Age-related Macular Degeneration

        12.4.9. Others (Ovarian Cancer, Fallopian Tube cancer, Prostate

    12.5. Market Value Forecast, by Distribution Channel, 2017–2031

        12.5.1. Hospital Pharmacies

        12.5.2. Retail Pharmacies

        12.5.3. Online Pharmacies

    12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.6.1. China

        12.6.2. Japan

        12.6.3. India

        12.6.4. Australia & New Zealand

        12.6.5. Rest of Asia Pacific

    12.7. Market Attractiveness Analysis

        12.7.1. By Type

        12.7.2. By Application

        12.7.3. By Distribution Channel

        12.7.4. By Country/Sub-region

13. Latin America Targeted Therapeutics Market Analysis and Forecast

    13.1. Introduction

    13.2. Key Findings

    13.3. Market Value Forecast, by Type, 2017–2031

        13.3.1. Monoclonal Antibodies

            13.3.1.1. Angiogenesis Inhibitors

            13.3.1.2. HER-2 Targeted Agents

            13.3.1.3. Anti-CD20 Monoclonal Antibodies

        13.3.2. Small Molecule

            13.3.2.1. Tyrosine Kinase Inhibitors

                13.3.2.1.1. mTOR Inhibitors

                13.3.2.1.2. PARP Inhibitors

    13.4. Market Value Forecast, by Application, 2017–2031

        13.4.1. Breast Cancer

        13.4.2. Colorectal Cancer

        13.4.3. Leukemia

        13.4.4. Lung Cancer

        13.4.5. Lymphoma

        13.4.6. Multiple Sclerosis

        13.4.7. Renal Cancer

        13.4.8. Wet Age-related Macular Degeneration

        13.4.9. Others (Ovarian Cancer, Fallopian Tube cancer, Prostate

    13.5. Market Value Forecast, by Distribution Channel, 2017–2031

        13.5.1. Hospital Pharmacies

        13.5.2. Retail Pharmacies

        13.5.3. Online Pharmacies

    13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.6.1. Brazil

        13.6.2. Mexico

        13.6.3. Rest of Latin America

    13.7. Market Attractiveness Analysis

        13.7.1. By Type

        13.7.2. By Application

        13.7.3. By Distribution Channel

        13.7.4. By Country/Sub-region

14. Middle East & Africa Targeted Therapeutics Market Analysis and Forecast

    14.1. Introduction

    14.2. Key Findings

    14.3. Market Value Forecast, by Type, 2017–2031

        14.3.1. Monoclonal Antibodies

            14.3.1.1. Angiogenesis Inhibitors

            14.3.1.2. HER-2 Targeted Agents

            14.3.1.3. Anti-CD20 Monoclonal Antibodies

        14.3.2. Small Molecule

            14.3.2.1. Tyrosine Kinase Inhibitors

                14.3.2.1.1. mTOR Inhibitors

                14.3.2.1.2. PARP Inhibitors

    14.4. Market Value Forecast, by Application, 2017–2031

        14.4.1. Breast Cancer

        14.4.2. Colorectal Cancer

        14.4.3. Leukemia

        14.4.4. Lung Cancer

        14.4.5. Lymphoma

        14.4.6. Multiple Sclerosis

        14.4.7. Renal Cancer

        14.4.8. Wet Age-related Macular Degeneration

        14.4.9. Others (Ovarian Cancer, Fallopian Tube cancer, Prostate

    14.5. Market Value Forecast, by Distribution Channel, 2017–2031

        14.5.1. Hospital Pharmacies

        14.5.2. Retail Pharmacies

        14.5.3. Online Pharmacies

    14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.6.1. GCC Countries

        14.6.2. South Africa

        14.6.3. Rest of Middle East & Africa

    14.7. Market Attractiveness Analysis

        14.7.1. By Type

        14.7.2. By Application

        14.7.3. By Distribution Channel

        14.7.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)

    15.2. Market Share Analysis, by Company (2022)

    15.3. Company Profiles

        15.3.1. Sanofi

            15.3.1.1. Company Overview

            15.3.1.2. Type Portfolio

            15.3.1.3. SWOT Analysis

            15.3.1.4. Financial Overview

            15.3.1.5. Strategic Overview

        15.3.2. GlaxoSmithKline plc

            15.3.2.1. Company Overview

            15.3.2.2. Type Portfolio

            15.3.2.3. SWOT Analysis

            15.3.2.4. Financial Overview

            15.3.2.5. Strategic Overview

        15.3.3. Takeda Pharmaceutical Company Ltd.

            15.3.3.1. Company Overview

            15.3.3.2. Type Portfolio

            15.3.3.3. SWOT Analysis

            15.3.3.4. Financial Overview

            15.3.3.5. Strategic Overview

        15.3.4. Merck & Co., Inc.

            15.3.4.1. Company Overview

            15.3.4.2. Type Portfolio

            15.3.4.3. SWOT Analysis

            15.3.4.4. Financial Overview

            15.3.4.5. Strategic Overview

        15.3.5. Novartis AG

            15.3.5.1. Company Overview

            15.3.5.2. Type Portfolio

            15.3.5.3. SWOT Analysis

            15.3.5.4. Financial Overview

            15.3.5.5. Strategic Overview

        15.3.6. Pfizer Inc.

            15.3.6.1. Company Overview

            15.3.6.2. Type Portfolio

            15.3.6.3. SWOT Analysis

            15.3.6.4. Financial Overview

            15.3.6.5. Strategic Overview

        15.3.7. F. Hoffmann-La Roche Ltd.

            15.3.7.1. Company Overview

            15.3.7.2. Type Portfolio

            15.3.7.3. SWOT Analysis

            15.3.7.4. Financial Overview

            15.3.7.5. Strategic Overview

        15.3.8. AstraZeneca

            15.3.8.1. Company Overview

            15.3.8.2. Type Portfolio

            15.3.8.3. SWOT Analysis

            15.3.8.4. Financial Overview

            15.3.8.5. Strategic Overview

        15.3.9. Seagen, Inc.

            15.3.9.1. Company Overview

            15.3.9.2. Type Portfolio

            15.3.9.3. SWOT Analysis

            15.3.9.4. Financial Overview

            15.3.9.5. Strategic Overview

        15.3.10. Bayer AG

            15.3.10.1. Company Overview

            15.3.10.2. Type Portfolio

            15.3.10.3. SWOT Analysis

            15.3.10.4. Financial Overview

            15.3.10.5. Strategic Overview

        15.3.11. Amgen, Inc.

            15.3.11.1. Company Overview

            15.3.11.2. Type Portfolio

            15.3.11.3. SWOT Analysis

            15.3.11.4. Financial Overview

            15.3.11.5. Strategic Overview

        15.3.12. Bristol-Myers Squibb Company

            15.3.12.1. Company Overview

            15.3.12.2. Type Portfolio

            15.3.12.3. SWOT Analysis

            15.3.12.4. Financial Overview

            15.3.12.5. Strategic Overview

List of Tables

Table 01: Global Targeted Therapeutics Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 02: Global Targeted Therapeutics Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 03: Global Targeted Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global Targeted Therapeutics Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Targeted Therapeutics Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America Targeted Therapeutics Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 07: North America Targeted Therapeutics Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 08: North America Targeted Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe Targeted Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe Targeted Therapeutics Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 11: Europe Targeted Therapeutics Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 12: Europe Targeted Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Asia Pacific Targeted Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Targeted Therapeutics Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 15: Asia Pacific Targeted Therapeutics Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 16: Asia Pacific Targeted Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 17: Latin America Targeted Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Latin America Targeted Therapeutics Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 19: Latin America Targeted Therapeutics Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 20: Latin America Targeted Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Middle East & Africa Targeted Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa Targeted Therapeutics Market Size (US$ Mn) Forecast, by Type, 2017–2031

Table 23: Middle East & Africa Targeted Therapeutics Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 24: Middle East & Africa Targeted Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global Targeted Therapeutics Market Size (US$ Mn) and Distribution (%), by Region, 2022–2031

Figure 02: Global Targeted Therapeutics Market Revenue (US$ Mn), by Type, 2022

Figure 03: Global Targeted Therapeutics Market Value Share, by Type, 2022

Figure 04: Global Targeted Therapeutics Market Revenue (US$ Mn), by Application, 2022

Figure 05: Global Targeted Therapeutics Market Value Share, by Application, 2022

Figure 06: Global Targeted Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2022

Figure 07: Global Targeted Therapeutics Market Value Share, by Distribution Channel, 2022

Figure 08: Global Targeted Therapeutics Market Value Share, by Region, 2022

Figure 09: Global Targeted Therapeutics Market Value (US$ Mn) Forecast, 2023–2031

Figure 10: Global Targeted Therapeutics Market Value Share Analysis, by Type, 2022–2031

Figure 11: Global Targeted Therapeutics Market Attractiveness Analysis, by Type, 2023–2031

Figure 12: Global Targeted Therapeutics Market Value Share Analysis, by Application, 2022–2031

Figure 13: Global Targeted Therapeutics Market Attractiveness Analysis, by Application, 2023–2031

Figure 14: Global Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031

Figure 15: Global Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 16: Global Targeted Therapeutics Market Value Share Analysis, by Region, 2022–2031

Figure 17: Global Targeted Therapeutics Market Attractiveness Analysis, by Region, 2023–2031

Figure 18: North America Targeted Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 19: North America Targeted Therapeutics Market Attractiveness Analysis, by Country, 2023–2031

Figure 20: North America Targeted Therapeutics Market Value Share Analysis, by Country, 2022–2031

Figure 21: North America Targeted Therapeutics Market Value Share Analysis, by Type, 2022–2031

Figure 22: North America Targeted Therapeutics Market Value Share Analysis, by Application, 2022–2031

Figure 23: North America Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031

Figure 24: North America Targeted Therapeutics Market Attractiveness Analysis, by Type, 2023–2031

Figure 25: North America Targeted Therapeutics Market Attractiveness Analysis, by Application, 2023–2031

Figure 26: North America Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 27: Europe Targeted Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 28: Europe Targeted Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 29: Europe Targeted Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031

Figure 30: Europe Targeted Therapeutics Market Value Share Analysis, by Type, 2022–2031

Figure 31: Europe Targeted Therapeutics Market Value Share Analysis, by Application, 2022–2031

Figure 32: Europe Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031

Figure 33: Europe Targeted Therapeutics Market Attractiveness Analysis, by Type, 2023–2031

Figure 34: Europe Targeted Therapeutics Market Attractiveness Analysis, by Application, 2023–2031

Figure 35: Europe Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 36: Asia Pacific Targeted Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 37: Asia Pacific Targeted Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 38: Asia Pacific Targeted Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031

Figure 39: Asia Pacific Targeted Therapeutics Market Value Share Analysis, by Type, 2022–2031

Figure 40: Asia Pacific Targeted Therapeutics Market Value Share Analysis, by Application, 2022–2031

Figure 41: Asia Pacific Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031

Figure 42: Asia Pacific Targeted Therapeutics Market Attractiveness Analysis, by Type, 2023–2031

Figure 43: Asia Pacific Targeted Therapeutics Market Attractiveness Analysis, by Application, 2023–2031

Figure 44: Asia Pacific Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 45: Latin America Targeted Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 46: Latin America Targeted Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 47: Latin America Targeted Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031

Figure 48: Latin America Targeted Therapeutics Market Value Share Analysis, by Type, 2022–2031

Figure 49: Latin America Targeted Therapeutics Market Value Share Analysis, by Application, 2022–2031

Figure 50: Latin America Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031

Figure 51: Latin America Targeted Therapeutics Market Attractiveness Analysis, by Type, 2023–2031

Figure 52: Latin America Targeted Therapeutics Market Attractiveness Analysis, by Application, 2023–2031

Figure 53: Latin America Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 54: Middle East & Africa Targeted Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 55: Middle East & Africa Targeted Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 56: Middle East & Africa Targeted Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022–2031

Figure 57: Middle East & Africa Targeted Therapeutics Market Value Share Analysis, by Type, 2022–2031

Figure 58: Middle East & Africa Targeted Therapeutics Market Value Share Analysis, by Application, 2022–2031

Figure 59: Middle East & Africa Targeted Therapeutics Market Value Share Analysis, by Distribution Channel, 2022–2031

Figure 60: Middle East & Africa Targeted Therapeutics Market Attractiveness Analysis, by Type, 2023–2031

Figure 61: Middle East & Africa Targeted Therapeutics Market Attractiveness Analysis, by Application, 2023–2031

Figure 62: Middle East & Africa Targeted Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Copyright © Transparency Market Research, Inc. All Rights reserved